

## SpineGuard reports on its Annual Shareholders' Meeting of June 30, 2022

**PARIS and BOULDER (CO), June 30, 2022 – 6:00pm CEST** - **SpineGuard** (FR0011464452 – ALSGD), an innovative company that deploys its DSG (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of bone implants, reports on its Annual Shareholders' Meeting held on June 30, 2022, at 10:00am, on its second call at the offices of the law firm Ashurst Paris, located at 18 square Edouard VII, 75009 Paris.

The shareholders present or represented were holding 7,847,972 shares representing a quorum of 25.14%.

All the resolutions of this Annual General Meeting were adopted with the exception of the 17<sup>th</sup> resolution as recommended by the Board of Directors.

The minutes of the shareholders' meeting will be available within the legal deadlines on SpineGuard's website: <u>www.spineguard.com</u>.

## **Upcoming financial events:**

- H1 2022 revenue, July 12, 2022, after market
- H1 2022 results, September 14, 2022, after market

## About SpineGuard®

Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG<sup>®</sup> (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices that have been used in over 90,000 surgical procedures worldwide. Nineteen studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG<sup>®</sup> offers to patients, surgeons, surgical staff and hospitals. Building on these strong fundamentals and several strategic partnerships, SpineGuard has expanded the scope of its DSG<sup>®</sup> technology in innovative applications such as the « smart » pedicle screw, the DSG Connect visualization and registration interface, dental implantology and surgical robotics. DSG<sup>®</sup> was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. SpineGuard has engaged in multiple ESG initiatives.

For further information, visit www.spineguard.com

## Disclaimer

The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.

Contacts:

SpineGuard

Pierre Jérôme CEO & Chairman Tel: +33 1 45 18 45 19 <u>p.jerome@spineguard.com</u>

SpineGuard Manuel Lanfossi CFO Tel: +33 1 45 18 45 19 m.lanfossi@spineguard.com NewCap Investor Relations & Financial Communication Mathilde Bohin / Pierre Laurent Tel.: +33 1 44 71 94 94 spineguard@newcap.eu

